![肿瘤药物治疗方案及综合评价](https://wfqqreader-1252317822.image.myqcloud.com/cover/13/43604013/b_43604013.jpg)
上QQ阅读APP看本书,新人免费读10天
设备和账号都新为新人
局部晚期鼻咽癌诱导化疗
方案Ⅱ PF+ CCRT vs CCRT
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T34_292_725_2040_1369_147312.jpg?sign=1739306179-gczzJxkCSYDwXoD2A6DhZ79G24dSl5k7-0-7c19d590c2ec252ae3397d1d80a0ccf8)
方案评价
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T34_285_1455_2043_2780_147313.jpg?sign=1739306179-7zaSE7GgTLJhSZLIL5RAZI5HNE2wRptx-0-c747a135a43603b3318dbdd21d56b6d4)
续表
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T35_226_339_1964_1772_146910.jpg?sign=1739306179-Ps4PVFXtZelOMD48cZba1zlhp3PiSdnn-0-401a57e0f66b2308d415881f3e956e97)
点评
本研究为Ⅲ期多中心随机对照试验,旨在评价诱导化疗方案PF(2周期)在局部晚期鼻咽癌(Ⅲ~ⅣB期,除外T3N0~1)治疗中的作用。研究结果显示,与单纯同步放化疗相比,2周期PF诱导化疗能改善局部晚期鼻咽癌的肿瘤控制,尤其在控制远处转移上有优势,但在总生存上无明显优势。该研究为诱导化疗+同步放化疗的治疗模式提供了研究基础。
(彭星辰 谢钰鑫)
参考文献
[1] CAO SM,YANG Q,GUO L,et al.Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:a phaseⅢ multicentre randomised controlled trial.Eur J Cancer,2017:14-23.